Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals director shows confidence with on-market share purchase

The company has begun discussions with International key opinion leaders for mucopolysaccharidoses (MPS) clinical trial design and site selection.
asx boards
Paradigm is focused on repurposing the drug pentosan polysulfate sodium.

Paradigm Biopharmaceuticals Ltd (ASX:PAR) director Christopher Fullerton has purchased 100,000 shares on-market for a total consideration of $118,116.

The transaction brings Fullerton’s total holding (direct and indirect) to 836,000 shares.

READ: Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial

The company has begun discussions with International key opinion leaders (KOL’s) for mucopolysaccharidoses (MPS) clinical trial design and site selection.

MPS is a progressive rare disease caused by the absence or malfunctioning of lysosomal enzymes and has a severe unmet need.

Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form (iPPS), a US FDA approved drug that has a long track record of safely treating inflammation.

The company is confident that a single successful phase 2/3 clinical trial will enable iPPS to be registered as a treatment for certain MPS indications.

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use